US 9,808,458 B2
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
Sanjay A. Desai, Potomac, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Washington, DC (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Washington, DC (US)
Filed on Mar. 17, 2016, as Appl. No. 15/72,902.
Application 15/072,902 is a division of application No. 14/111,256, granted, now 9,320,786, previously published as PCT/US2012/033072, filed on Apr. 11, 2012.
Claims priority of provisional application 61/474,583, filed on Apr. 12, 2011.
Prior Publication US 2016/0193207 A1, Jul. 7, 2016
Int. Cl. A61K 31/496 (2006.01); A61K 31/501 (2006.01); C07D 413/14 (2006.01); C07D 409/04 (2006.01); C07D 409/14 (2006.01); C07D 239/84 (2006.01); C07D 417/06 (2006.01); C07D 241/44 (2006.01); C07D 263/57 (2006.01); C07D 491/048 (2006.01); C07D 498/04 (2006.01); C07D 277/54 (2006.01); C07D 513/04 (2006.01); C07D 281/16 (2006.01); A61K 31/42 (2006.01); A61K 31/433 (2006.01); A61K 31/495 (2006.01); A61K 31/498 (2006.01); A61K 31/50 (2006.01); A61K 31/519 (2006.01); A61K 31/554 (2006.01); C07K 14/445 (2006.01); A61K 31/422 (2006.01); A61K 31/4741 (2006.01); A61K 31/517 (2006.01); A61K 39/015 (2006.01); C07K 16/20 (2006.01); A61K 45/06 (2006.01); A61K 31/423 (2006.01); A61K 31/427 (2006.01); A61K 31/4355 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01)
CPC A61K 31/501 (2013.01) [A61K 31/42 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/427 (2013.01); A61K 31/433 (2013.01); A61K 31/437 (2013.01); A61K 31/4355 (2013.01); A61K 31/4439 (2013.01); A61K 31/4741 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/50 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/554 (2013.01); A61K 39/015 (2013.01); A61K 45/06 (2013.01); C07D 239/84 (2013.01); C07D 241/44 (2013.01); C07D 263/57 (2013.01); C07D 277/54 (2013.01); C07D 281/16 (2013.01); C07D 409/04 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 491/048 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07K 14/445 (2013.01); C07K 16/205 (2013.01); C07K 2319/21 (2013.01); C07K 2319/43 (2013.01)] 24 Claims
 
1. A method of treating malaria in an animal comprising administering an effective amount of a compound of formula (I) to the animal:
Q-Y—R1—R2  (I),
wherein:
Q is a dioxo heterocyclyl ring fused to an aryl group, is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, mercapto, alkoxy, alkylthio, nitro, cyano, amino, alkyl, aryl, hydroxyalkyl, haloalkyl, cyanoalkyl, aminoalkyl, alkylamino, dialkylamino, carboxy, carboxyalkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, ureido, and formyl;
Y is SO2;
R1 is piperazinyl, which is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, mercapto, alkoxy, alkylthio, nitro, cyano, amino, alkyl, hydroxyalkyl, haloalkyl, cyanoalkyl, aminoalkyl, alkylamino, dialkylamino, carboxy, carboxyalkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, ureido, and formyl;
R2 is aryloxyalkyl, which is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, mercapto, alkoxy, alkylthio, nitro, cyano, amino, alkyl, hydroxyalkyl, haloalkyl, cyanoalkyl, aminoalkyl, alkylamino, dialkylamino, carboxy, carboxyalkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, ureido, and formyl;
or a pharmaceutically acceptable salt thereof.